New York, New York (PRWEB) April 23, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is addressing safety concerns and other issues related to Plavix in light of a Wall Street Journal* article published on April 22, 2013. The article reviews several drugs that are at the center of deceptive marketing lawsuits filed by state authorities; the drugs include Johnson & Johnson’s Risperdal, GlaxoSmithKline’s Avandia and Sanofi Aventis, and Bristol-Myers Squibb’s Plavix. The attorneys general of West Virginia and Mississippi have taken action against makers of Plavix, alleging, among other things, that they made false and misleading claims about the superiority of the blood thinner compared to Aspirin.
“For years, there has been mounting evidence suggesting that Plavix manufacturers put patients at risk by failing to properly warn about this drug,” said Daniel C. Burke, Senior Litigation Counsel at Parker Waichman LLP. “These legal actions help support those suspicions. Our firm continues to receive inquiries from Plavix users who allege that the medication caused injuries such as gastrointestinal and cerebral hemorrhaging.” The national personal injury firm has filed a number of lawsuits on behalf of Plavix patients. One case, for example, was filed on behalf of a Georgia man on Sept. 28, 2012, in the Supreme Court of the State of New York, County of New York (Index No. 156776/2012).
West Virginia and Mississippi allege that Plavix makers made deceptive marketing claims by stating that Plavix is superior to Aspirin, the Journal reports. Both states also allege that the companies should have known that Plavix may not be properly metabolized in a certain subgroup of patients.
Last month, Sanofi, in a filing** with the U.S. Securities and Exchange Commission noted that it was being investigated by the U.S. Department of Justice over discl
Copyright©2012 Vocus, Inc.
All rights reserved